Researchers present 26 studies at ATS 2024, covering topics such as OSA prevalence, CPAP’s impact on hospitalization and mortality, and the effect of weight change on CPAP use.


Summary: At ATS 2024, ResMed-supported researchers will present 26 studies highlighting the rising prevalence of obstructive sleep apnea (OSA) and the critical role of CPAP therapy. Key topics include the impact of CPAP on hospitalization and mortality rates, the effects of weight change on CPAP usage, and comprehensive insights into managing OSA in various patient populations. Additionally, ResMed will showcase its latest respiratory care innovations at the conference.

Key Takeaways: 

  • The studies highlight the increasing prevalence of obstructive sleep apnea and the significant impact of CPAP therapy on reducing hospitalization and all-cause mortality rates.
  • Research underscores the effect of weight change on CPAP usage, providing valuable insights for managing sleep apnea in patients with varying weight conditions.
  • ResMed showcases its latest advancements in respiratory care, including the AirCurve 11 bilevel devices and the AirFit F40 CPAP mask, aimed at improving patient outcomes.

Twenty-six ResMed-supported abstracts are being presented at the ATS 2024 International Conference, showing the increased prevalence of obstructive sleep apnea and the critical role of CPAP therapy. 

Highlights include:

  • Treatment of Sleep-Disordered Breathing with Adaptive Servo-Ventilation (READ-ASV)
    in Opioid Users – a European Registry
    • Presented by Jean-Louis Pepin, MD, Grenoble Alpes University, France
  • An Estimate of the Prevalence of Obstructive Sleep Apnea in the United States into 2050
    • Presented by Elroy Boers, PhD, ResMed Science Center
  • All-Cause Mortality in Obstructive Sleep Apnea
    • Presented by Atul Malhotra, MD, University of California, San Diego
  • Impact of Positive Airway Pressure (PAP) Therapy on Hospitalization in Obstructive Sleep Apnea (OSA): Analysis of a German Healthcare Database
    • Presented by Holger Woehrle, MD, Ulm Lung Centre, Germany
  • Treatment of Sleep-Disordered Breathing with Adaptive Servo-Ventilation – Outcomes in Patients with Treatment-Emergent or Persistent Central Sleep Apnea
    • Presented by Michael Arzt, MD, Universitätsklinikum Regensburg, Germany

Monica Mallampalli, chief executive officer at Alliance of Sleep Apnea Partners, and Carlos Nunez, ResMed Chief Medical Officer, are presenting as part of the Innovations Hub on the topic of “Healthcare of Today, Looking Towards Tomorrow: Digital Innovations and Patient Centricity.”

At the conference, ResMed also is showing its latest innovations in respiratory care at its booth. These innovations include the AirCurve 11 bilevel devices, which enable healthcare providers to make informed decisions about care, deliver personalized support, and drive therapy outcomes for sleep apnea patients, and its AirFit F40, its smallest full-face CPAP mask.

The complete list of ResMed-sponsored studies being presented at ATS 2024 are:

Treatment of sleep-disordered breathing with adaptive servo-ventilation (READ-ASV) in opioid users – a European registrySunday, May 19, 20249:15 AM -11:15 AM
8-year Trends in Obesity, Type 2 Diabetes, and Glucagon-like Peptide-1 (GLP-1) Use in Patients With Obstructive Sleep ApneaSunday May 19, 20249:15 AM – 11:15 AM
Impact of CPAP Termination on Permanent Work Disability in Obstructive Sleep Apnea: A French Nationwide Alaska Database AnalysisSunday May 19, 20249:15 AM – 4:15 PM
Tailoring Social Support to Improve PAP Therapy Usage in Obstructive Sleep ApneaSunday May 19, 20249:15 AM – 4:15 PM
Examining Alignment of Patient Medication-taking Behaviors With Inhaler Usage Recommendations in Chronic Obstructive Pulmonary Disease and AsthmaSunday May 19, 20249:15 AM – 4:15 PM
Using Natural Language Processing for Qualitative Research: Insights From a Real-world AnalysisSunday May 19, 20249:15 AM – 4:15 PM
A Qualitative Analysis of Perceptions and Awareness of Air Pollution and Its Health Effects in Asthma Among Asthma-care Professionals Across Southern CaliforniaMonday May 20, 20249:15 AM – 4:15 PM
An Estimate of the Prevalence of Obstructive Sleep Apnea in the United States Into 2050Monday May 20, 20249:15 AM – 4:15 PM
All-cause Mortality in Obstructive Sleep Apnea: Systematic Literature Review Including Randomised Trials and Confounding Adjusted Non-randomised Controlled Studies and Meta-analysis of Positive Airway Pressure TreatmentMonday May 20, 20242:15 PM – 4:15 PM
Impact of Positive Airway Pressure (PAP) Therapy on Hospitalization in Obstructive Sleep Apnea (OSA): Analysis of a German Healthcare DatabaseMonday May 20, 20242:15 PM – 4:15 PM
Hypoxic Burden but Not AHI Predicts Risk of Cardiovascular Events: A Secondary Analysis of the RICCADSA Clinical TrialMonday May 20, 20242:15 PM – 4:15 PM
A Digital Quality Improvement Program Delivered By Clinical Pharmacists Can Reduce Acute Care Visits In COPDMonday May 20, 20242:15 PM – 4:15 PM
Hands-on Simulation Training With Home Ventilators Improves PCCM Fellow Understanding of Nocturnal NIV in Chronic HypercapniaMonday May 20, 20242:15 PM – 4:15 PM
The Economic and Health Burden of COPD in North America Through 2050: A Scenario Analysis Based on Two Large Data SourcesTuesday May 21, 20249:15 AM – 11:15 AM
Impact of long-term domiciliary noninvasive ventilation (NIV) on severe exacerbations and survival in Patients with Chronic Obstructive Pulmonary Disease (COPD): a nationwide cohort study using multistate modelsTuesday May 21, 20249:15 AM – 11:15 AM
Nocturnal Hypoxemic Burden and Micro- and Macrovascular Disease in Patients With Type 2 DiabetesTuesday May 21, 20249:15 AM – 11:15 AM
Risk Factors for Severe Exacerbation Occurrence Among Patients With COPD-OSA Overlap Syndrome Using Bilevel Positive Airway Pressure TherapyTuesday May 21, 20249:15 AM – 4:15 PM
Adherence to Glucagon-like Peptide-1 Receptor Agonists (GLP-1s) in Obstructive Sleep Apnea Patients With and Without Type 2 DiabetesTuesday May 21, 20242:15 PM – 4:15 PM
Treatment of sleep-disordered breathing with adaptive servo-ventilation (READ-ASV) – outcomes in patients with treatment-emergent or persistent central sleep apnea (TE-CSA) in a European registryTuesday, May 21, 20242:15 PM – 4:15 PM
A Scenario-based Modeling Study to Project the Future Burden of COPD in the United States Accounting for the Effects of E-cigarettesTuesday May 21, 20242:15 PM – 4:15 PM
The Impact Of Weight Change On Positive Airway Pressure Use In Patients With Obstructive Sleep Apnea And ObesityTuesday May 21, 20242:15 PM – 4:15 PM
Real World GLP-1 Adherence in Patients with Treated Obstructive Sleep ApneaTuesday May 21, 20242:15 PM – 4:15 PM
Less REM Sleep Predicts Mortality in Adults With Coronary Artery Disease and Obstructive Sleep Apnea: The RICCADSA TrialTuesday May 21, 20242:15 PM – 4:15 PM
Gender Specific Differences in a National Sample of Individuals with Comorbid Insomnia, Obstructive Sleep Apnea (OSA), and DepressionWednesday May 22, 20248:15 AM – 10:15 AM
Use of Weight Management Regimens Among Positive Airway Pressure-Treated Patients With Obstructive Sleep Apnea and ObesityWednesday May 22, 202411:00 AM – 1:00 PM
A Mixed-methods Exploration of Patient Perspectives on Pap Therapy Initiation: Implications for Improved Outreach and EducationWednesday May 22, 202411:00 AM – 1:00 PM

Photo caption: ResMed AirCurve 11

File photo